Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists - ScienceDirect
Indication extrapolation for anti-TNF biosimilars | Nature Reviews Gastroenterology & Hepatology
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement | European Respiratory Society
![ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents) -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9c2bef2d-312b-4053-ba48-b71a92fccf08/gr1_lrg.jpg "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents) -")
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents) -
Drug Insight: different mechanisms of action of tumor necrosis factor antagonists—passive-aggressive behavior? | Nature Reviews Rheumatology
Etanercept for the treatment of rheumatoid arthritis | Immunotherapy
Cureus | Biologic Therapies in Sarcoidosis and Uveitis: A Review
Frontiers | Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology | Immunology
Striking a new path – extending the diagnostic portfolio by test systems for therapeutic drug monitoring - EUROIMMUNBlog
Anti-TNF therapy | Musculoskeletal Key
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists | Journal of Pharmacology and Experimental Therapeutics
Tumor Necrosis Factor-Alpha Inhibitory Therapy for Non-Infectious Autoimmune Uveitis | IntechOpen
Antibodies | Free Full-Text | Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy | HTML
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation - Clinical Gastroenterology and Hepatology
Use of Biologic Agents in the Treatment of Uveitis
Biologic Response Modifiers Inbrel, Remicade, Humira and the Innate Immune Response: Images and Animations in Arthritis and Rheumatism page 30
Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor
Schematic illustrations summarizing similarities and differences... | Download Scientific Diagram
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls | Immunotherapy
Anti-TNF-α therapies: the next generation | Nature Reviews Drug Discovery
References in Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management - The Lancet Infectious Diseases
Tumor Necrosis Factor (TNF) Inhibitors | SpringerLink
Structure (A); and mechanisms of action (B) of anti-TNF biologics. All... | Download Scientific Diagram
TNF Inhibitor - an overview | ScienceDirect Topics
Schematic of TNF inhibitors and their mode of action. Receptor (i.e.... | Download Scientific Diagram
Overview of TNF Inhibitors for Treating Inflammatory Bowel Disease
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls | Immunotherapy
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
